Abstract
Association of a recombinational repair protein RAD51 with tumor suppressors BRCA1 and BRCA2 suggests that defects in homologous recombination are responsible for tumor formation. Also recent findings that a protein associated with the MRE11/RAD50 repair complex is mutated in Nijmegen breakage syndrome characterized by increased cancer incidence and ionizing radiation sensitivity strongly support this idea. However, the direct roles of BRCA proteins and the protein responsible for NBS in recombinational repair are not clear though they are associated with the recombinational repair complexes. Since RAD51 forms a complex with other members of the RAD52 epistasis group and with BRCA proteins, it is reasonable to ask if alterations of members of the RAD52 epistasis group lead to tumor development. Here we describe missense mutations at functional regions of RAD54 and the absence of the wild-type RAD54 expression resulting from aberrant splicing in primary cancers. Since RAD54 is a recombinational protein associated with RAD51, this is the first genetic evidence that cancer arises from a defect in repair processes involving homologous recombination.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bang DD, Verhage R, Goosen N, Brouwer J and van der Putte P. . 1992 Nucl. Acids Res. 20: 3925–3931.
Bezzubova O, Silbergleit A, Yamaguchi-Iwai Y, Takeda S and Buerstedde J-M. . 1997 Cell 89: 185–193.
Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates III JR, Hays L, Morgan WF and Petrini JHJ. . 1998 Cell 93: 477–486.
Chomczynski P and Sacchi N. . 1987 Anal. Biochem. 162: 156–159.
Eisen JA, Sweder KS and Hanawalt PC. . 1995 Nucl. Acids Res. 14: 2715–2723.
Emery HS, Schild D, Kellogg DE and Mortimer RK. . 1991 Gene 104: 103–106.
Essers J, Hendriks RW, Swagemakers SMA, Troelstra C, de Wit J, Bootsma D, Hoeijmakers JHJ and Kanaar R. . 1997 Cell 89: 195–204.
Girdham CH and Glover DM. . 1991 Genes Dev. 5: 1786–1799.
Golub EI, Kovalenko OV, Gupta RC, Ward DC and Radding CM. . 1997 Nucl. Acids Res. 25: 4106–4110.
Kanaar R, Troelstra C, Swagemakers SMA, Essers J, Smit B, Franssen J-H, Pastink A, Bezzubova OY, Buerstedde J-M, Clever B, Heyer W-D and Hoeijmakers JHJ. . 1996 Curr. Biol. 6: 828–838.
Laurent BC, Treitel MA and Carlson M. . 1991 Proc. Natl. Acad. Sci. USA 88: 2687–2691.
Matsuura S, Tauchi H, Nakamura A, Kondo N, Sakamoto S, Endo S, Sweets D, Solder B, Belohradsky BH, Der Kaloustian VM, Oshimura M, Isomura M, Nakamura Y and Komatsu K. . 1998 Nature Genet. 19: 179–181.
Peterson CL and Tamkun JW. . 1995 Trends Biochem. Sci. 20: 143–146.
Rasio D, Murakumo Y, Robbins D, Roth T, Silver A, Negrini M, Schmidt C, Burczak J, Fishel R and Croce CM. . 1997 Cancer Res. 57: 2378–2383.
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T and Livingston DM. . 1997 Cell 88: 265–275.
Sharan SK, Morimatsu M, Albrecht U, Lim D-S, Regel E, Dinh C, Sands A, Eichele G, Hasty P and Bradley A. . 1997 Nature 386: 804–810.
Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Hirai H, Ishikawa F, Takaku F. . 1991 Blood 77: 1153–1156.
Swagemakers SMA, Essers J, de Wit J, Hoeijmakers JHJ and Kanaar R. . 1998 J. Biol. Chem. 273: 28292–28297.
Tamkun JW, Deuring R, Scott MP, Kissinger M, Pattatucci AM, Kaufman TC and Kennison JA. . 1992 Cell 68: 561–572.
Thai TH, Du F, Tsan JT, Jin Y, Phung A, Spillman MA, Massa HF, Muller CY, Ashfaq R, Mathis JM, Miller DS, Trask BJ, Baer R and Bowcock AM. . 1998 Hum. Molec. Genet. 7: 195–202.
Troelstra C, van Gool A, de Wit J, Vermeulen W, Bootsma D and Hoeijmakers JHJ. . 1992 Cell 71: 939–953.
Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, Beckmann G, Seemanova E, Cooper PR, Nowak NJ, Stumm M, Weemaes CMR, Gatti RA, Wilson RK, Digweed M, Rosenthal A, Sperling K, Concannon P and Reis A. . 1998 Cell 93: 467–476.
Acknowledgements
We thank T Nishioka for photographic work. This work was supported by Grants-in-Aid for Cancer Research from the Ministry of Education, Science and Culture, Japan, and by Tsuchiya Medical Research Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matsuda, M., Miyagawa, K., Takahashi, M. et al. Mutations in the RAD54 recombination gene in primary cancers. Oncogene 18, 3427–3430 (1999). https://doi.org/10.1038/sj.onc.1202692
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202692
Keywords
This article is cited by
-
BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system
Clinical and Translational Oncology (2022)
-
Sequencing for germline mutations in Swedish breast cancer families reveals novel breast cancer risk genes
Scientific Reports (2021)
-
Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report
BMC Gastroenterology (2020)
-
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma
Endocrine (2020)
-
In vitro studies of DNA damage and repair mechanisms induced by BNCT in a poorly differentiated thyroid carcinoma cell line
Radiation and Environmental Biophysics (2018)